B. Riley Securities Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $31

B. Riley Securities analyst Madison El-Saadi has maintained a 'Buy' rating on Eton Pharmaceuticals (NASDAQ: ETON) and raised the price target from $26 to $31. This adjustment reflects a positive outlook for the company's stock performance.